Zevra Therapeutics (ZVRA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.23
- Estimate
- $0.18
- Surprise
- +30.2%
- Revenue (period 2026-09-30)
- $37.8M
- Score today
- 6.9/10
Revenue source: xbrl.
How the report landed
Zevra Therapeutics (ZVRA) beat the $0.18 estimate with adjusted EPS of $0.23 — a large 30.2% upside surprise.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ZVRA Buy (Wait) at 6.9/10; no pre/post engine snapshot brackets this report.
4 of the last 4 quarters beat the estimate; this quarter's +30.2% surprise compares with a +127.2% four-quarter average.
What supports the rating
- V7 flight-to-quality bonus: +0.5 (Q=8.7 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: MIPLYFFA (82.0%)
- Negative momentum
- Elevated risk factors
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $10.26
- Entry target
- $9.87
- Price target
- $21.97
- Stop
- $9.18
- Upside to target
- +114.1%
- Reward-to-risk
- 14.0:1
At 10.9× trailing and 9.5× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.
ZVRA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $609.3M
- P/E (fwd)
- 9.5
- P/E (ttm)
- 10.9
- 52-week range
- $8.01–$15.04
- Off 52-week high
- 31.8%
- RSI (14)
- 50
- Volume vs avg
- 0.99×
- Score today
- 6.9/10